Oralair^®: sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis

References

• Ciprandi G, Puccinelli P, Scurati S et al. Characteristics of rhinitis and asthma in patients referring to allergy specialist. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology. London, UK, 5–9 June 2010 (P1698).
   Google Scholar
• Ciprandi G, Incorvaia C, Puccinelli P, Scurati S, Masieri S, Frati F. The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients. Int. J. Immunopathol. Pharmacol.23(2), 637–640 (2010).
   PubMed Web of Science ®Google Scholar
• Noon L, Cantab BC. Prophylactic inoculation against hay fever. Lancet177(4580), 1572–1573 (1911).
   Google Scholar
• Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J. Allergy Clin. Immunol.93(3), 556–566 (1994).
   PubMed Web of Science ®Google Scholar
• Lofkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farina in adults with perennial allergic rhinoconjunctivitis. Allergy49(2), 100–107 (1994).
   PubMed Web of Science ®Google Scholar
• Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann. Allergy Asthma Immunol.77(1), 74–80 (1996).
   PubMed Web of Science ®Google Scholar
• Lowell FC, Frankline W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N. Engl. J. Med.273(13), 675–679 (1965).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.85(3), 606–611 (1990).
   PubMedGoogle Scholar
• Del Prete A, Loffredo C, Carderopoli A, Caparello O, Verde R, Sebastian A. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthal. (Copenh.)72(5), 631–634 (1994).
   PubMed Web of Science ®Google Scholar
• Gaglani B, Borish L, Bartelson BL, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced allergic rhinitis. Ann. Allergy Asthma Immunol.79(3), 259–265 (1997).
   PubMedGoogle Scholar
• Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I.Clinical results. Allergy41(2), 131–140 (1986).
   PubMedGoogle Scholar
• Balda BR, Wolf H, Baumgarten C et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy53(8), 740–748 (1998).
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol.120(6), 1338–1345 (2007).
   PubMed Web of Science ®Google Scholar
• Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J. Allergy Clin. Immunol.111(3), 437–448; quiz 449 (2003).
   PubMed Web of Science ®Google Scholar
• Morris DL. Treatment of respiratory disease with ultra-small doses of antigens. Ann. Allergy28(10), 494–500 (1970).
   PubMedGoogle Scholar
• Horak F, Stubner P, Berger UE, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J. Investig. Allergol. Clin. Immunol.8(3), 165–171 (1998).
   PubMed Web of Science ®Google Scholar
• Mascarell L, Saint-Lu N, Moussu H et al. Macrophage-like cells play a crucial role in tolerance induction via the sublingual route. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology. London, UK, 5–9 June 2010.
   Google Scholar
• Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy64(Suppl. 91), 1–59 (2009).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J. Allergy Clin. Immunol.113(6), 1129–1136 (2004).
   PubMed Web of Science ®Google Scholar
• Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol.79(4), 660–677 (1987).
   PubMed Web of Science ®Google Scholar
• Calderon M, Mosges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy65(4), 420–434 (2010).
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol.121(2), 512–518 e2 (2008).
   PubMed Web of Science ®Google Scholar
• Pradalier A, Basset D, Claudel A et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy54(8), 819–828 (1999).
   PubMed Web of Science ®Google Scholar
• Didier A. Future developments in sublingual immunotherapy. Allergy61(Suppl. 81), 29–31 (2006).
   PubMedGoogle Scholar
• Moingeon P, Hrabina M, Bergmann KC et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int. Arch. Allergy Immunol.146(4), 338–342 (2008).
   PubMed Web of Science ®Google Scholar
• Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy40(4), 598–606 (2010).
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J. Allergy Clin. Immunol.124(3), 471–477, 477 e1 (2009).
   PubMed Web of Science ®Google Scholar
• Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin. Exp. Allergy39(3), 401–408 (2009).
   PubMed Web of Science ®Google Scholar
• Machida H, Nakagami T, Watanabe I. Local ocular immunotherapy for experimental allergic conjunctivitis. Jpn J. Ophthalmol.44(6), 634–638, (2000).
   PubMedGoogle Scholar
• Magone MT, Chan CC, Beck L, Whitcup SM, Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol.30(7), 1841–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Liu G, Clark L, Ono SJ. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest. Ophthalmol. Vis. Sci.41(12), 3850–3855 (2000).
   PubMed Web of Science ®Google Scholar
• Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol. Rev.179, 102–118 (2001).
   PubMed Web of Science ®Google Scholar
• Moingeon P. Recombinant allergens for sublingual immunotherapy. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology. London, UK, 5–9 June 2010.
   Google Scholar